

Claudia A Palafox-Sánchez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7581407/publications.pdf>

Version: 2024-02-01

50
papers

901
citations

516710

16
h-index

526287

27
g-index

51
all docs

51
docs citations

51
times ranked

1389
citing authors

#	ARTICLE	IF	CITATIONS
1	ICOS Gene Polymorphisms (IVS1 + 173 T/C and c. 1624 C/T) in Primary Sjögren's Syndrome Patients: Analysis of ICOS Expression. <i>Current Issues in Molecular Biology</i> , 2022, 44, 764-776.	2.4	3
2	Analysis of <i>TNFSF13B</i> polymorphisms and <i>BAFF</i> expression in rheumatoid arthritis and primary Sjögren's syndrome patients. <i>Molecular Genetics & Genomic Medicine</i> , 2022, 10, e1950.	1.2	7
3	Cytokine profiles and clinical characteristics in primary Sjögren's syndrome patient groups. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23629.	2.1	7
4	The <i>rs675 4G/5G PAI-1</i> polymorphism confers genetic susceptibility to systemic lupus erythematosus, its clinical manifestations, and comorbidities in Mexican-Mestizo population. <i>Autoimmunity</i> , 2020, 53, 71-77.	2.6	5
5	Expression of BAFF and BAFF receptors in primary Sjögren's syndrome patients with ectopic germinal center-like structures. <i>Clinical and Experimental Medicine</i> , 2020, 20, 615-626.	3.6	26
6	Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. <i>Scientific Reports</i> , 2020, 10, 6236.	3.3	16
7	Association of <i>CD28</i> and <i>CTLA4</i> haplotypes with susceptibility to primary Sjögren's syndrome in Mexican population. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22620.	2.1	6
8	Assessment of CD40 and CD40L expression in rheumatoid arthritis patients, association with clinical features and DAS28. <i>Clinical and Experimental Medicine</i> , 2019, 19, 427-437.	3.6	17
9	Association of soluble CD40 levels with <i>CD40</i> polymorphism and chronic kidney disease in systemic lupus erythematosus. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e1014.	1.2	10
10	Letter to the editor: "The association of CD40 polymorphism (rs1883832C/T) and soluble CD40 with the risk of systemic lupus erythematosus among Egyptian patients". <i>Clinical Rheumatology</i> , 2019, 38, 1529-1530.	2.2	2
11	B cell activating factor receptor expression is associated with germinal center B cell maintenance. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 2053-2060.	1.8	9
12	High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in <i>TNFSF13B</i> gene. <i>Clinical and Experimental Medicine</i> , 2019, 19, 183-190.	3.6	32
13	<i>PTPN22</i> rs1858C>T polymorphism is associated with increased CD154 expression and higher CD4+ T cells percentage in rheumatoid arthritis patients. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22710.	2.1	4
14	BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus. <i>Cytokine</i> , 2019, 114, 115-127.	3.2	27
15	<i>PTPN22</i> rs788 G>A (R263Q) Polymorphism is Associated with mRNA Expression but it is not a Susceptibility Marker for Rheumatoid Arthritis Patients from Western Mexico. <i>Biochemical Genetics</i> , 2019, 57, 455-465.	1.7	2
16	Analysis of Electronic Apex Locators in Human Teeth Diagnosed With Apical Periodontitis. <i>Brazilian Dental Journal</i> , 2019, 30, 550-554.	1.1	4
17	A 60 kDa prolactin variant secreted by cervical cancer cells modulates apoptosis and cytokine production. <i>Oncology Reports</i> , 2018, 39, 1253-1260.	2.6	7
18	Association of extrapituitary prolactin promoter polymorphism with disease susceptibility and anti-RNP antibodies in Mexican patients with systemic lupus erythematosus. <i>Archives of Medical Science</i> , 2018, 14, 1025-1032.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Aberrant expression of interleukin-10 in rheumatoid arthritis: Relationship with IL10 haplotypes and autoantibodies. <i>Cytokine</i> , 2017, 95, 88-96.	3.2	27
20	Polimorfismo $\hat{\sim}$ 1123G>C en el gen PTPN22 y anticuerpos anti pĂ©ptido citrulinado cĂ©lico en la artritis reumatoide. <i>Medicina ClĂ©nica</i> , 2017, 149, 95-100.	0.6	6
21	Association ofPTPN22Haplotypes ($\hat{\sim}$ 1123G>C/+1858C>T) with Rheumatoid Arthritis in Western Mexican Population. <i>International Journal of Genomics</i> , 2017, 2017, 1-5.	1.6	7
22	Micro-CT study of the root canal anatomy of maxillary canines. <i>Journal of Clinical and Experimental Dentistry</i> , 2017, 9, e1230-e1236.	1.2	5
23	PTPN22 $\hat{\sim}$ 1123G>C polymorphism and anti-cyclic citrullinated protein antibodies in rheumatoid arthritis. <i>Medicina ClĂ©nica (English Edition)</i> , 2017, 149, 95-100.	0.2	2
24	Frequency distribution of interleukin-10 haplotypes (-1082 A>G, -819 C>T, and -592 C>A) in a Mexican population. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.2	5
25	TNFR1-383 AĂ©C polymorphism association with clinical manifestations in primary SjĂ©grenĂ©™s syndrome patients. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.2	3
26	<i>KIR2DL2</i> and <i>KIR2DS2</i> as genetic markers to the methotrexate response in rheumatoid arthritis patients. <i>Immunopharmacology and Immunotoxicology</i> , 2016, 38, 303-309.	2.4	15
27	Distribution of PTPN22 polymorphisms in SLE from western Mexico: correlation with mRNA expression and disease activity. <i>Clinical and Experimental Medicine</i> , 2016, 16, 399-406.	3.6	22
28	Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 582-592.	1.6	108
29	Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. <i>Clinical and Experimental Immunology</i> , 2015, 182, 119-131.	2.6	47
30	Polymorphisms and functional haplotype in PADI4: Further evidence for contribution on rheumatoid arthritis susceptibility and anti-cyclic citrullinated peptide antibodies in a western Mexican population. <i>Immunology Letters</i> , 2015, 163, 214-220.	2.5	22
31	Analysis of IL10 haplotypes in primary SjĂ©grenĂ©™s syndrome patients from Western Mexico: Relationship with mRNA expression, IL-10 soluble levels, and autoantibodies. <i>Human Immunology</i> , 2015, 76, 473-479.	2.4	6
32	Association of interleukin-10 promoter haplotypes with disease susceptibility and IL-10 levels in Mexican patients with systemic lupus erythematosus. <i>Clinical and Experimental Medicine</i> , 2015, 15, 439-446.	3.6	14
33	Removal of an Instrument Fractured by Ultrasound and the Instrument Removal System under Visual Magnification. <i>Journal of Contemporary Dental Practice</i> , 2015, 16, 238-242.	0.5	3
34	FAS -670A>G promoter polymorphism is associated with soluble Fas levels in primary SjĂ©grenĂ©™s syndrome. <i>Genetics and Molecular Research</i> , 2014, 13, 4831-4838.	0.2	9
35	Debris Remaining in the Apical Third of Root Canals after Chemomechanical Preparation by Using Sodium Hypochlorite and Glyde: An InĂ©vivo Study. <i>Journal of Endodontics</i> , 2014, 40, 1419-1423.	3.1	14
36	Macrophage migration inhibitory factor: Association of $\hat{\sim}$ 794 CATT5Ă©8 and $\hat{\sim}$ 173 G>C polymorphisms with TNF- $\hat{\pm}$ in systemic lupus erythematosus. <i>Human Immunology</i> , 2014, 75, 433-439.	2.4	39

#	ARTICLE	IF	CITATIONS
37	The extrapituitary prolactin promoter polymorphism is associated with rheumatoid arthritis and anti-CCP antibodies in Mexican population. <i>Gene</i> , 2013, 525, 130-135.	2.2	12
38	Macrophage migration inhibitory factor (MIF): Genetic evidence for participation in early onset and early stage rheumatoid arthritis. <i>Cytokine</i> , 2013, 61, 759-765.	3.2	59
39	The +1858C/T PTPN22 gene polymorphism confers genetic susceptibility to rheumatoid arthritis in Mexican population from the Western Mexico. <i>Immunology Letters</i> , 2012, 147, 41-46.	2.5	34
40	Associations of Killer Cell Immunoglobulin-Like Receptor Genes with Rheumatoid Arthritis. <i>Disease Markers</i> , 2012, 33, 201-206.	1.3	25
41	The functional class evaluated in rheumatoid arthritis is associated with soluble TGF- β 21 serum levels but not with G915C (Arg25Pro) TGF- β 21 polymorphism. <i>Rheumatology International</i> , 2012, 32, 367-372.	3.0	15
42	Associations of killer cell immunoglobulin-like receptor genes with rheumatoid arthritis. <i>Disease Markers</i> , 2012, 33, 201-6.	1.3	16
43	Plasminogen activator inhibitor-1 polymorphisms (\sim 844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables. <i>Clinical and Experimental Medicine</i> , 2011, 11, 11-17.	3.6	4
44	High prevalence of autoantibodies to RNA helicase A in Mexican patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R6.	3.5	18
45	A Functional Ser413/Ser413 PAI-2 Polymorphism Is Associated With Susceptibility and Damage Index Score in Systemic Lupus Erythematosus. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 233-238.	1.7	13
46	Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis. <i>Clinical and Experimental Medicine</i> , 2009, 9, 223-228.	3.6	5
47	Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 332-335.	1.1	17
48	Expression of ICAM1 and VCAM1 Serum Levels in Rheumatoid Arthritis Clinical Activity. Association with Genetic Polymorphisms. <i>Disease Markers</i> , 2009, 26, 119-126.	1.3	42
49	Oxidized Low-Density Lipoprotein/ β 2-Glycoprotein I Complexes and Autoantibodies to oxLig-1/ β 2-Glycoprotein I in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. <i>American Journal of Clinical Pathology</i> , 2004, 121, 426-436.	0.7	51
50	Oxidized Low-Density Lipoprotein/ β 2-Glycoprotein I Complexes and Autoantibodies to oxLig-1/ β 2-Glycoprotein I in Patients With Systemic Lupus Erythematosus and Antiphospholipid Syndrome. <i>American Journal of Clinical Pathology</i> , 2004, 121, 426-436.	0.7	25